mk 0663 has been researched along with substance p in 1 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (substance p) | Trials (substance p) | Recent Studies (post-2010) (substance p) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 17,289 | 277 | 2,010 |
| Protein | Taxonomy | mk 0663 (IC50) | substance p (IC50) |
|---|---|---|---|
| Substance-P receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Substance-K receptor | Rattus norvegicus (Norway rat) | 0.2 | |
| Substance-K receptor | Homo sapiens (human) | 0.2455 | |
| Substance-P receptor | Homo sapiens (human) | 0.0011 | |
| Neuromedin-K receptor | Homo sapiens (human) | 0.125 | |
| Substance-K receptor | Mesocricetus auratus (golden hamster) | 0.148 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almeida, A; Baltazar, F; Castro, AG; Cruz, A; Lamas, N; Lima-Rodrigues, M; Oliveira, P; Pedrosa, J; Reis, RM; Valle-Fernandes, A; Vieira, A | 1 |
1 other study(ies) available for mk 0663 and substance p
| Article | Year |
|---|---|
The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
Topics: Animals; Calcitonin Gene-Related Peptide; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Interleukin-10; Interleukin-1beta; Interleukin-6; Laryngitis; Male; Pyridines; Rats; Rats, Wistar; Substance P; Sulfones; Tumor Necrosis Factor-alpha | 2010 |